Alcon initiates post-approval study for Hydrus Microstent malposition rates
Alcon Research is conducting a post-approval study to assess the malposition rate of the Hydrus Microstent within 24 months after implantation.
Phase III
Ophthalmology / Glaucoma
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of a post-approval study for the Hydrus Microstent is significant as it will provide essential data on malposition rates, which could influence its safety profile and market competitiveness. Monitoring the outcomes will be crucial for understanding potential risks and benefits in clinical practice.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results on malposition rates and any clinical sequelae reported during the 24-month follow-up.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.